Radioactive Isotope of the Month

Welcome to Radioactive Isotope of the Month, where we focus on a different isotope each month, highlighting its characteristics, applications, and safety considerations.

This month’s feature: Yttrium-90 (Y-90).

Quick Facts about Y-90

• Half-life: Approximately 64 hours (about 2.67 days)

• Decay mode: Beta decay

• Primary use: Cancer treatment, particularly in targeted radionuclide therapy such as radioembolization for liver cancer

• Energy: Emits beta particles with a maximum energy of 2.28 MeV

  
  

Y-90 in Medicine

Y-90 plays a critical role in modern medicine, especially in radioembolization procedures. In these treatments, tiny beads containing Y-90 are injected into the blood vessels feeding a tumor, delivering a concentrated dose of radiation directly to cancer cells while minimizing exposure to surrounding healthy tissue.

Beyond liver cancer treatment, Y-90 is also used in:

• Radionuclide therapy for non-Hodgkin’s lymphoma

• Palliative care to reduce bone pain caused by metastatic cancers

  
  

Radiation Safety Considerations

Despite Y-90’s beta emissions having limited penetration (around 5 mm in tissue), proper handling and shielding are essential. Materials like glass, acrylic, or plastic are commonly used to protect against bremsstrahlung radiation produced when beta particles interact with dense materials such as lead.

For healthcare facilities working with Y-90, a strong radiation safety program should include:

• Dosimetry monitoring for all personnel

• Routine contamination checks following isotope handling

• Clear protocols for spill management and waste disposal

  
  

Need Guidance on Y-90 Safety?

If your facility uses Y-90 or is considering adding it to your treatment options, we’re here to help you navigate the necessary precautions and procedures. Contact us to learn more about how we can support your nuclear radiation safety program.

Join us next month as we explore another important isotope.